Scynexis (SCYX) Net Income towards Common Stockholders Growth (5y) (2018 - 2026)
Powered by 
Analysis
Scynexis (SCYX) Net Income towards Common Stockholders Growth (5y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -44.39% |
| Mar 31, 2026 | -28.53% |
| Dec 31, 2025 | 19.32% |
| Sep 30, 2025 | -62.84% |
| Jun 30, 2025 | -1.53% |
| Mar 31, 2025 | 5.09% |
| Dec 31, 2024 | 15.43% |
| Sep 30, 2024 | 18.77% |
| Jun 30, 2024 | -11.46% |
| Mar 31, 2024 | 15.26% |
| Dec 31, 2023 | -30.28% |
| Sep 30, 2023 | 22.97% |
| Jun 30, 2023 | 77.68% |
| Mar 31, 2023 | -35.40% |
| Dec 31, 2022 | 4.28% |
| Sep 30, 2022 | -34.73% |
| Jun 30, 2022 | -13.70% |
| Mar 31, 2022 | 2.83% |
| Dec 31, 2021 | -32.99% |
| Sep 30, 2021 | 38.10% |